Eagle Pharmaceuticals Reports Third Quarter 2019 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Eagle Pharmaceuticals Reports Third Quarter 2019 Results

Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 31c, Revenues Miss

November 12, 2019 6:53 AM EST

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.26, $0.31 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $41.15 million versus the consensus estimate of $48.49 million.

Invested $12 million in research and development and external legal costs to advance Eagles pipeline.Eagles Japanese marketing partner, SymBio Pharmaceuticals Limited, submitted a New Drug Application (NDA) for TREAKISYM, bendamustine ready-to-dilute liquid formulation, in Japan in September. Approval is expected in Q4 2020, which would trigger a $5 million milestone payment to Eagle. Potential payments to Eagle could reach $10 to $25 million per year in royalties and... More